CHICAGO — Cardiosense has appointed John Martin, MD, MBA, a vascular surgeon and experienced medtech leader, as executive vice president and chief medical officer. Martin will guide clinical development and product strategy as the company advances its AI-powered cardiovascular monitoring platform toward commercial launch.
The announcement follows the FDA’s 510(k) clearance of Cardiosense’s CardioTag™ device, a noninvasive wearable designed to monitor cardiac function. The company is also pursuing De Novo classification for its first AI algorithm, which estimates pulmonary capillary wedge pressure (PCWP) without the need for implantable sensors.
“John’s rare combination of clinical expertise and medtech leadership is precisely what Cardiosense needs during this transformative phase,” said Amit Gupta, Cardiosense co-founder and CEO. “His leadership will accelerate our mission to expand access to personalized, noninvasive hemodynamic-guided care for the millions living with heart failure and other critical conditions.”
Martin previously held senior roles at Butterfly Network, where he worked to integrate advanced imaging and monitoring solutions into diverse care settings. He is a practicing vascular surgeon at the University of Maryland Vascular Center at Annapolis and founder of the Heart Health Foundation, a nonprofit focused on cardiovascular disease education, prevention, and early detection.
“Cardiosense is building something truly special at the intersection of AI and medicine,” Martin said. “We have the potential to transform how therapy is guided across multiple conditions by putting actionable, noninvasive hemodynamic data directly into clinicians’ and patients’ hands.”
The company’s recent SEISMIC-HF I study, published in JACC: Heart Failure, found that its wearable and AI algorithm could estimate PCWP with accuracy comparable to implantable devices. Editorial commentary noted strong performance across sex, race, BMI, and atrial fibrillation status, highlighting the potential to address limitations of current implantable sensors, which reach less than 1% of eligible heart failure patients.
Cardiosense aims to broaden adoption of hemodynamic-guided care beyond heart failure to other conditions such as renal disease and trauma, delivering solutions that are noninvasive, scalable, and more accessible.
